var data={"title":"Triamcinolone (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Triamcinolone (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390773?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=triamcinolone-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Triamcinolone (topical): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=triamcinolone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Triamcinolone (topical): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606513\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dermasorb TA;</li>\n      <li>Dermazone;</li>\n      <li>Kenalog;</li>\n      <li>Oralone;</li>\n      <li>Pediaderm TA [DSC];</li>\n      <li>Trianex;</li>\n      <li>Triderm</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606514\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kenalog;</li>\n      <li>Oracort;</li>\n      <li>Triaderm</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9608405\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606707\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatoses (corticosteroid-responsive):</b> Topical:<b> Note:</b>  Frequency of application based upon severity of condition</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cream, ointment: Apply thin film to affected areas 2 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lotion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">0.025%: Apply a thin film to affected area 3 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">0.1%: Apply a thin film to affected area 2 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aerosol solution: Apply to affected area 3 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oral inflammatory and ulcerative lesions:</b> Oral paste: Press a small amount (about <sup>1</sup>/<sub>4</sub> inch) to the lesion at bedtime; a larger quantity may be required for coverage of some lesions. For severe lesions, may be used 2 or 3 times daily after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650217\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=triamcinolone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Triamcinolone (topical): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatoses (corticosteroid-responsive):</b> Children and Adolescents: Topical: <b>Note:</b> Frequency based upon severity of condition: Cream, ointment, lotion, aerosol solution: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606708\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use the lowest effective dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650218\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650219\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606835\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kenalog: 0.147 mg/g (63 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.147 mg/g (63 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triderm: 0.1% (28.4 g, 85.2 g); 0.5% (454 g) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025% (15 g, 80 g, 453.6 g, 454 g); 0.1% (15 g, 30 g, 80 g, 453.6 g, 454 g); 0.5% (15 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermasorb TA: 0.1% [contains cetyl alcohol, milk protein, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pediaderm TA: 0.1% [DSC] [contains cetyl alcohol, methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025% (60 mL); 0.1% (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trianex: 0.05% (17 g [DSC], 85 g [DSC], 430 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025% (15 g, 80 g, 454 g); 0.1% (15 g, 30 g, 80 g, 453.6 g, 454 g); 0.5% (15 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Paste, Mouth/Throat, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oralone: 0.1% (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapy Pack, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermazone: 0.1% (1 ea) [contains propylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606542\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46682915\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Dermazone therapy pack is a kit containing triamcinolone acetonide cream 0.1% (80 g) and silicone gel sheets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606749\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol solution: For external use only. Avoid heat, flame or smoking when using. Avoid eyes and do not inhale if spraying near face. Container may be used upright or inverted. When using the spray button, spray at a distance of three to six inches from affected area. For hard to reach areas, insert the spray tube applicator into spray button and twist to seat. Point tube away from body and face. Be sure the tube applicator is clean prior to use and wash after use. Move spray tube while applying, touching the surface of the affected area. Do not use tight fitting diapers or plastic pants on a patient being treated in the diaper area, as this constitutes an occlusive dressing. Occlusive dressing may be used if instructed by a health care professional; monitor for infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, ointment: For external use only; avoid contact with eyes. Apply a thin film sparingly. May be used with occlusive dressings for management of psoriasis or recalcitrant conditions.  If an infection develops, discontinue use of occlusive dressings.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion: For external use only. Apply topical sparingly to affected areas as a thin film. May be used with occlusive dressings for management of psoriasis or recalcitrant conditions.  If an infection develops, discontinue use of occlusive dressings.  Not for ophthalmic use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral paste: Do not apply paste to skin or eyes. Apply small amount into oral cavity until thin, smooth film develops; do not rub in; spreading the paste may result in a granular, gritty sensation and crumbling; apply at bedtime to allow contact of the medication with the lesion overnight; if more frequent application necessary, apply after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606543\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dermatoses (corticosteroid-responsive):</b> Topical: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oral inflammatory and ulcerative lesions:</b> Oral paste: Adjunctive treatment and temporary relief of symptoms associated with oral inflammatory and ulcerative lesions resulting from trauma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606493\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kenalog may be confused with Ketalar</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606580\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Localized burning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acneiform eruption, allergic contact dermatitis, atrophic striae, folliculitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, pruritus, secondary skin infection, skin atrophy, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: HPA-axis suppression, hyperglycemia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606550\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to triamcinolone or any component of the formulation; fungal, viral, or bacterial infections of the mouth or throat (oral topical formulation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Oral topical formulations only:</i> Fungal, viral, or bacterial infections of the mouth or throat</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606551\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Aerosol solution: Do not apply to underarms or groin unless directed by a health care professional; if improvement is not seen within 2 weeks, contact prescriber. Product is flammable; avoid heat, smoking or flames when applying.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For external use only; avoid contact with eyes. Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; discontinue if skin irritation or contact dermatitis should occur; do not use in patients with decreased skin circulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; High-potency products: Avoid the use of high-potency steroids on the face.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral cavity application: Do not apply paste to skin or eyes. When used as a topical agent in the oral cavity, if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300168\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606610\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9964&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606545\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9887155\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth weight infants following maternal use of potent or very potent topical products, especially in high doses. Use of mild to moderate potency topical corticosteroids is preferred in pregnant females and the use of large amounts or use for prolonged periods of time should be avoided (Chi 2016; Chi 2017; Murase 2014). Also avoid areas of high percutaneous absorption (Chi 2017). The risk of stretch marks may be increased with use of topical corticosteroids (Murase 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9887157\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sufficient quantities of triamcinolone are absorbed following topical administration to produce detectable amounts in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Systemic corticosteroids are present in breast milk. Although the manufacturer recommends that caution be used, topical corticosteroids are generally considered acceptable for use in breastfeeding females (Butler 2014; WHO 2002). Do not apply topical corticosteroids to breast until breastfeeding ceases (Leachman 2006); hypertension was noted in a breastfed infant when a high potency topical corticosteroid was applied to the nipple (Butler 2014; Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650220\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HPA axis suppression and adrenal insufficiency, especially in children. When used in the oral cavity (topical paste), if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised. When using aerosol solution, if no improvement is seen within 2 weeks, re-evaluation is advised.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606655\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Triamcinolone has intermediate to high range potency (dosage-form dependent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606657\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Biologic: 18 to 36 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (40%); feces (60%, some via biliary excretion)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606837\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Kenalog External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.147 mg/g (63 g): $635.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Triamcinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.147 mg/g (100 g): $589.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Triamcinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (80 g): $11.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $5.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (15 g): $11.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Triderm External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (28.4 g): $426.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (454 g): $233.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Dermasorb TA External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (340.4 g): $621.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Triamcinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (60 mL): $37.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (60 mL): $90.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Triamcinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (80 g): $10.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $5.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (15 g): $10.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Trianex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (430 g): $1,083.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Paste</b> (Oralone Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 g): $89.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Paste</b> (Triamcinolone Acetonide Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 g): $80.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapy Pack</b> (Dermazone External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (1): $3,866.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962009\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adcortyl (IE);</li>\n      <li>Aftab (DE);</li>\n      <li>Aristocort (BD, LI);</li>\n      <li>Aristocort A (MY, TH);</li>\n      <li>Centocort (TH);</li>\n      <li>Cortefin (BD);</li>\n      <li>Cortiflex (PE);</li>\n      <li>Cutinolone (AE);</li>\n      <li>Delphi Creme (BE, NL);</li>\n      <li>Delphicort (AT, DE);</li>\n      <li>Dermacort (HK, LI, MY);</li>\n      <li>Facort (TH);</li>\n      <li>Ftoracort (EE);</li>\n      <li>Ftorocort (HU, VN);</li>\n      <li>Ftorokort (UA);</li>\n      <li>Gemicort (KR);</li>\n      <li>Generlog (TH);</li>\n      <li>Glytop (AR);</li>\n      <li>Invert Plaster (KR);</li>\n      <li>Kanolone (MY);</li>\n      <li>Kena-Lite (TH);</li>\n      <li>Kenacin A (JO);</li>\n      <li>Kenacort (PH, VE);</li>\n      <li>Kenacort A (NL);</li>\n      <li>Kenacort A in Orabase (CH);</li>\n      <li>Kenacort E (PE);</li>\n      <li>Kenacort T (FI, SE);</li>\n      <li>Kenacort-A (BH, EG, ID, KE, QA, TW, TZ, UG);</li>\n      <li>Kenacort-A in Orabase (NL);</li>\n      <li>Kenalog (CN, DK, JO, LI, PK);</li>\n      <li>Kenalog in Orabase (BH, ID, KW, SA, ZA);</li>\n      <li>Keno (SG);</li>\n      <li>Ketricin (ID);</li>\n      <li>Laver (TH);</li>\n      <li>Ledercort (AR, IN, PK);</li>\n      <li>Manolone (TH);</li>\n      <li>Metoral (TH);</li>\n      <li>Nincort (CN, TW);</li>\n      <li>Oracort (NZ);</li>\n      <li>Oracortia (VN);</li>\n      <li>Oramedy (HK, KR, SG);</li>\n      <li>Orrepaste (ET, LK, MY, SG);</li>\n      <li>Positon (TR);</li>\n      <li>Sinocort (ID);</li>\n      <li>Tess (IN);</li>\n      <li>Tramsone (ET);</li>\n      <li>Tricin (LK, PH);</li>\n      <li>Tricort (FI, PH);</li>\n      <li>Tricortone (AU);</li>\n      <li>Volon A Antibiotikafrei (AT, DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):761-773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/28233354/pubmed\" target=\"_blank\" id=\"28233354\">28233354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy. <i>JAMA Dermatol</i>. 2016;152(8):934-935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/27366995/pubmed\" target=\"_blank\" id=\"27366995\">27366995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dermasorb TA (triamcinolone acetonide) [prescribing information]. Johnson City, TN: Crown Laboratories, Inc.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kenalog spray (triamcinolone acetonide) [prescribing information]. Jacksonville, FL: Ranbaxy; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triamcinolone acetonide cream [prescribing information]. Newton, PA: Renaissance Pharma, Inc.; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triamcinolone acetonide dental paste [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals USA Inc; August 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triamcinolone acetonide lotion [prescribing information]. Marietta, GA: VersaPharm Incorporated; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triamcinolone acetonide ointment [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trianex (triamcinolone) [prescribing information]. Farmville, NC: CMP Pharma Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triderm (triamcinolone acetonide) [prescribing information]. Johnson City, TN: Crown Laboratories; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9964 Version 195.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9606513\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9606514\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9608405\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9606707\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45650217\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9606708\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45650218\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45650219\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9606835\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9606542\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46682915\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9606749\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9606543\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9606493\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9606580\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9606550\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9606551\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300168\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9606610\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9606545\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9887155\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9887157\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45650220\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9606655\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9606657\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9606837\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962009\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9964|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=triamcinolone-topical-patient-drug-information\" class=\"drug drug_patient\">Triamcinolone (topical): Patient drug information \t</a></li><li><a href=\"topic.htm?path=triamcinolone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Triamcinolone (topical): Pediatric drug information</a></li></ul></div></div>","javascript":null}